MEA Renal Disease Therapeutics Market

The size of the Middle East and Africa Renal Disease Therapeutics Market is predicted to grow at a sluggish rate between 2022 to 2027.

The increasing prevalence of renal diseases, chronic diseases such as diabetes, and the growing population across the MEA are majorly driving the renal disease therapeutics market. In addition, technological advancements in the healthcare sector are expected to boost the renal disease therapeutics market growth in this region. Also, the initiatives are taken by the government for creating awareness among the people about renal diseases, and the development of novel drugs and therapies is positively influencing the market growth.

The growing geriatric population in the region is considered the significant growth influential factor for the market growth. The diabetic population is suspectable to diabetes and other renal diseases, therefore; increasing the demand for the market growth. The growing demand for advanced diagnostics and therapeutics for diseases is expected to accelerate the market growth. Growing investments and funding by the government and non-government organizations in research and development activities and the advancement of infrastructure in the region encourage market growth.

Furthermore, an increasing number of individuals with insurance owing to the mandatory acts under the affordable care act boosts the market growth. In addition, growing awareness for acute and chronic kidney diseases is uplifting the demand for the MEA renal disease therapeutics market. To develop novel therapeutic procedures, the key participants in the market are adopting key strategies such as collaborations, acquisitions, and mergers to accelerate the regional market growth.

However, the high cost of treatment and the associated side effects with the various therapies are predicted to restrict the market growth.

This research report on the MEA renal disease therapeutics market has been segmented and sub-segmented into the following categories:

By Treatment:

• Dialysis Equipment
• Renal Denervation Devices
• Wearable Artificial Kidney Device
• Distal Embolic Protection Devices

By Application Mode:

• Kidney Stone Disease
• End-Stage Kidney Disease
• Kidney Failure
• Chronic Kidney Disease
• Hypertension
• Diabetes
• Anemia

By Country:

• KSA
• UAE
• Israel
• rest of GCC countries
• South Africa
• Ethiopia
• Kenya
• Egypt
• Sudan
• rest of MEA

The Middle East and Africa are expected to record a moderate share during the forecast period. The improving healthcare infrastructure in the emerging countries in the region is contributing to the market growth. Furthermore, the Y-O-Y growing prevalence of chronic diseases, rising population are increasing the demand for the market in the region. In addition, the FDA approvals the presence of key market players to fuel the market.  Furthermore, the emerging countries in the areas such as UAE, South Africa, and Saudi Arabia are expanding the regional market growth with a significant market share.

South Africa accounted for the largest share of the market, and it is most likely to register a significant share during the forecast period. The prevalence of renal diseases, growing demand for advanced and novel renal therapeutics, and rising healthcare expenditure propel market growth.

UAE is most likely to witness a promising share in the market during the forecast period owing to the growing geriatric population, high prevalence of diabetes, improving healthcare sector, and technological advances are boosting the market growth.

Similarly, on the other hand, Saudi Arabia is projected to showcase a considerable share in the market in the coming years. Increasing awareness, supportive government policies are surging the market growth.

KEY MARKET PLAYERS:

Some of the companies influencing the Middle East and Africa Renal disease therapeutics market are Amgen Inc., Merck & Co., Inc., Bristol-Myers Squibb Company, Hoffmann-La Roche Inc., Shire Inc., Fresenius Medical Care, Baxter International, and Davita Healthcare Partners.